Pivot Park Screening Centre unveils new insulin-regulated aminopeptidase inhibitors
Pivot Park Screening Centre unveils the discovery of new inhibitors of insulin-regulated aminopeptidase by a high-throughput screening of 400,000 drug-like compounds.
Pivot Park Screening Centre presents cutting-edge research on the quest for antiplatelet drugs. The focus of the research lies in ultra-high throughput-based screening for the discovery of antiplatelet drugs affecting receptor dependent calcium signaling dynamics.
Press release: National Chemical Landmark 2023
The Royal Netherlands Chemical Society (KNCV) will proclaim the Pharmacological Laboratory at Pivot Park in Oss a National Chemical Heritage on June 22, 2023. This building was the foundation for many chemical-pharmaceutical inventions with great social impact, including the birth control pill. Prior to the unveiling of the plaque, a lecture program on the role of this property in chemical-pharmaceutical history, the present and the future will take place. The program is open to the public at no cost; register at www.kncv.nl/nce.
Pivot Park Screening Center has Assay Development Fund available for early drug discovery project
The Assay Development Fund supports scientists in the Netherlands that are working with or aiming to work with a charity for an early drug discovery project, by providing expertise in assay development.
ELRIG: LABEL-FREE MASS SPECTROMETRY ASSAYS FOR EARLY DRUG DISCOVERY
This symposium aims to highlight the recent advances and applications of label-free high-throughput cell-based and affinity-selection mass spectrometry (MS) screening assay technologies as an emerging lead discovery strategy.
Growth Fund invests 325 million euros in Oncode-PACT to accelerate the development of cancer drugs.
The National Growth Fund invests 325 million euros in the Oncode-PACT plan to accelerate the preclinical development process of cancer drugs.
PPSC and CeMOS have formed a strategic partnership to provide industry-leading joint early drug discovery services, with an emphasis on label-free “cell-based” target-centric, phenotypic, and functional MALDI MS assays for ultra-High-Throughput Screening (uHTS), hit-to-lead biological profiling and in-vitro DMPK/ADME-T.
or call
Pivot Park – Building RK
Kloosterstraat 9
5349 AB Oss
The Netherlands
+31 (0)412 – 84 60 10
info@pivotpark.com
Pivot Park Exploitatie B.V.
Building OP
Kloosterstraat 9
5349 AB Oss
The Netherlands
10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.
We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.
The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.
Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.
This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.
We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.
Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.